# Tocilizumab

## Actemra inj 162mg/0.9mL

#### 一般高價藥

| 藥品代碼       | IACTM                                                                                                                                                                                                                                                                                                                                                                                        |
|:---------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Moderate to severe active RA in adult patients， given alone or in combination w/ methotrexate (MTX) &/or other DMARDs.                                                                                                                                                                                                                                                                      |
| 用法用量       | SC， rheumatoid arthritis， giant cell arteritis <100 kg 162 mg once every other week; increase to 162 mg once every week based on clinical response> or =100 kg 162 mg once every week.                                                                                                                                                                                                     |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                 |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                 |
| 禁忌           | Hypersensitivity to tocilizumab.                                                                                                                                                                                                                                                                                                                                                             |
| 副作用         | Upper resp tract infections， cellulitis， oral herpes simplex， herpes zoster; abdominal pain， mouth ulceration， gastritis; rash， pruritus， urticaria; headache， dizziness; increased hepatic transaminases， increased wt; HTN; leucopenia， neutropenia; hypercholesterolaemia; peripheral oedema， hypersensitivity reaction， inj site reaction; cough， dyspnoea; conjunctivitis. |
| 孕期用藥建議   | No (limited) human data – probably compatible                                                                                                                                                                                                                                                                                                                                                |
| 哺乳期用藥建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                          |

## Actemra Infusion 80mg/4mL/Vial (限Covid-19用)

#### 個案臨採

| 藥品代碼       | IACTMV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:---------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Rheumatoid Arthritis (RA); Polyarticular Juvenile Idiopathic Arthritis (pJIA); Systemic Juvenile Idiopathic Arthritis (sJIA).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 用法用量       | TFDA新型冠狀病毒（SARS-CoV-2）感染臨床處置暫行指引第十一版: 與dexamethasone合併用於嚴重肺炎以上(未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器、使用機械式呼吸器或ECMO)之病患；或與dexamethasone + remdesivir 合併用於未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器之病患。病患住院3天內，且入住ICU 24小時內或未入住ICU但發炎指數上升(CRP>=7.5 mg/dL) 。劑量：8mg/kg，單次靜脈注射，至多800mg [Micromedex 20210623] COVID-19 (Severe) - Pneumonia 8 mg/kg (actual body weight) as single IV dose， MAX dose 800 mg; give in combination with dexamethasone 6 mg IV or orally daily for up to 10 days or another corticosteroid at an equivalent dose (guideline dosage)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 禁忌           | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 副作用         | Common Cardiovascular: Hypertension (Adult， 4% to 6% ) Dermatologic: Injection site reaction ( Rheumatoid arthritis， 2.4% to 10.1% ; polyarticular juvenile idiopathic arthritis， 28.8% ; systemic juvenile idiopathic arthritis， 41.2% )， Rash (Rheumatoid arthritis， 2% to 4% ) Gastrointestinal: Diarrhea (Pediatric， greater than 5% )， Upper abdominal pain (Adult， 2% to 3% ) Hepatic: ALT/SGPT level raised (Rheumatoid arthritis， 0.7% to 48%; polyarticular or systemic juvenile idiopathic arthritis， 4% to 13% )， Aspartate aminotransferase serum level raised (Rheumatoid arthritis， 0.1% to 41%; polyarticular or systemic juvenile idiopathic arthritis， less than 1% to 5% ) Neurologic: Dizziness (Adult， 2% to 3% )， Headache (Adults， 5% to 7%; pediatric， greater than 5% ) Respiratory: Nasopharyngitis (Rheumatoid arthritis， 4% to 7%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Infusion reaction (Rheumatoid arthritis， 7% to 8%; polyarticular juvenile idiopathic arthritis， 16% to 20.2% ) Serious Gastrointestinal: Gastrointestinal perforation， Pancreatitis Hematologic: Decreased platelet count (1% to 4% )， Neutropenia (Rheumatoid arthritis， 1.8% to 3.7% ; polyarticular or systemic juvenile idiopathic arthritis， 7% to 15.4% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis， Hypersensitivity reaction (Up to 0.9% )， Opportunistic infection， Tuberculosis Respiratory: Upper respiratory infection (Rheumatoid arthritis， 6% to 8%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Cancer， Severe infectious disease |
| 孕期用藥建議   | No (limited) human data – probably compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 哺乳期用藥建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

## ACTEMRA Infusion 200mg/10mL/Vial (限Covid-19用)

#### 個案臨採

| 藥品代碼       | IACTMV10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:---------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Rheumatoid Arthritis (RA); Polyarticular Juvenile Idiopathic Arthritis (pJIA); Systemic Juvenile Idiopathic Arthritis (sJIA).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 用法用量       | TFDA新型冠狀病毒（SARS-CoV-2）感染臨床處置暫行指引第十一版: 與dexamethasone合併用於嚴重肺炎以上(未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器、使用機械式呼吸器或ECMO)之病患；或與dexamethasone + remdesivir 合併用於未使用吸氧治療下SpO2=<94%、需使用吸氧治療、高流量氧氣或非侵襲性呼吸器之病患。病患住院3天內，且入住ICU 24小時內或未入住ICU但發炎指數上升(CRP>=7.5 mg/dL) 。劑量：8mg/kg，單次靜脈注射，至多800mg [Micromedex 20210623] COVID-19 (Severe) - Pneumonia 8 mg/kg (actual body weight) as single IV dose， MAX dose 800 mg; give in combination with dexamethasone 6 mg IV or orally daily for up to 10 days or another corticosteroid at an equivalent dose (guideline dosage)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 肝功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 腎功能異常     | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 禁忌           | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 副作用         | Common Cardiovascular: Hypertension (Adult， 4% to 6% ) Dermatologic: Injection site reaction ( Rheumatoid arthritis， 2.4% to 10.1% ; polyarticular juvenile idiopathic arthritis， 28.8% ; systemic juvenile idiopathic arthritis， 41.2% )， Rash (Rheumatoid arthritis， 2% to 4% ) Gastrointestinal: Diarrhea (Pediatric， greater than 5% )， Upper abdominal pain (Adult， 2% to 3% ) Hepatic: ALT/SGPT level raised (Rheumatoid arthritis， 0.7% to 48%; polyarticular or systemic juvenile idiopathic arthritis， 4% to 13% )， Aspartate aminotransferase serum level raised (Rheumatoid arthritis， 0.1% to 41%; polyarticular or systemic juvenile idiopathic arthritis， less than 1% to 5% ) Neurologic: Dizziness (Adult， 2% to 3% )， Headache (Adults， 5% to 7%; pediatric， greater than 5% ) Respiratory: Nasopharyngitis (Rheumatoid arthritis， 4% to 7%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Infusion reaction (Rheumatoid arthritis， 7% to 8%; polyarticular juvenile idiopathic arthritis， 16% to 20.2% ) Serious Gastrointestinal: Gastrointestinal perforation， Pancreatitis Hematologic: Decreased platelet count (1% to 4% )， Neutropenia (Rheumatoid arthritis， 1.8% to 3.7% ; polyarticular or systemic juvenile idiopathic arthritis， 7% to 15.4% ) Hepatic: Hepatotoxicity Immunologic: Anaphylaxis， Hypersensitivity reaction (Up to 0.9% )， Opportunistic infection， Tuberculosis Respiratory: Upper respiratory infection (Rheumatoid arthritis， 6% to 8%; systemic juvenile idiopathic arthritis， 5% or higher ) Other: Cancer， Severe infectious disease |
| 孕期用藥建議   | No (limited) human data – probably compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 哺乳期用藥建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

